P721 Early vedolizumab trough levels are associated with induction therapy outcome
Volume: 14, Issue: Supplement_1, Pages: S580 - S580
Published: Jan 1, 2020
Abstract
Background Vedolizumab (VDZ) is a monoclonal antibody which targets a4b7 integrin. It has been demonstrated to have efficacy in the induction and maintenance of remission in patients with both ulcerative colitis (UC) and Crohn’s disease (CD). We aimed to determine factors, including drug levels, associated with success of VDZ induction therapy. Methods Patients were recruited prospectively from three Irish Academic Medical Centres. Individuals...
Paper Details
Title
P721 Early vedolizumab trough levels are associated with induction therapy outcome
Published Date
Jan 1, 2020
Volume
14
Issue
Supplement_1
Pages
S580 - S580
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History